Pyronaridine/artesunate

Pyronaridine/artesunate - a fixed dose artemisinin-based combination therapy (act) consisting of artesunate, a semi-synthetic derivative of the sesquiterpine lactone, and pyronaridine, a benzonaphthyridine derivative, with anti-malarial and potential antiviral activities. Upon oral administration of artesunate/pyronaridine and hydrolysis of artesunate's active endoperoxide bridge moiety by liberated heme in parasite-infected red blood cells (rbcs), reactive oxygen species and carbon-centered radicals form, which damage and kill parasitic organisms. Pyronaridine inhibits the formation of beta-hematin, which results in the accumulation of toxic heme within the parasite. In addition, pyronaridine inhibits glutathione-dependent degradation of hematin. This promotes hematin-induced lysis of rbcs, resulting in parasite death. Artesunate/pyronaridine may also exhibit antiviral activity against some viruses by modulating the type-1 interferon (ifn) pathway.

Resources

Latest articles - Pyronaridine/artesunate

• Most recent articles
• Ongoing trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Pyronaridine/artesunate for any updates.

‎